Ligand validation:6LH1

A6L: 2,3-dihydroxypropyl (9Z)-octadec-9-enoate

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6LH1_A6L_A_402	23%	55%	0.245	0.872	0.83	0.91	2	2	0	0	100%	1
6LH1_A6L_A_403	19%	61%	0.242	0.839	0.83	0.67	2	1	0	0	100%	1
6LGV_A6L_A_402	16%	54%	0.222	0.792	0.81	0.95	2	1	0	0	100%	1
6LGY_A6L_A_405	11%	59%	0.235	0.753	0.88	0.69	2	1	0	0	100%	1
6LGZ_A6L_A_502	10%	60%	0.286	0.79	0.8	0.74	2	1	1	0	100%	1
6LH0_A6L_A_502	7%	61%	0.331	0.797	0.8	0.68	2	1	0	0	100%	1
6A94_A6L_B_3004	28%	38%	0.254	0.945	1.23	1.18	2	2	0	0	80%	0.8
7QOA_A6L_A_504	17%	71%	0.178	0.87	0.37	0.74	-	-	0	0	36%	0.36

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.